Machine learning integrated with biology at scale lies at the core of insitro’s approach to rethinking drug discovery and development. In this role you will contribute to the core biology platform that insitro is building by working as a key member of the team working on many aspects of imaging technology such as imaging technology development support, image acquisition QC, screening assay optimization, screening execution at scale and automation development. A successful candidate will play a role on cross-functional teams that encompass research biology, engineering and data science disciplines to design experiments, develop novel iPSC models at scale, and develop large, innovative disease relevant-biological datasets using cutting edge, high-throughput automation platforms. You will possess strong interpersonal skills, a strong collaborative work ethic, ability to adapt to changing needs, and the capacity to multitask to meet key goals. Strong communication and presentation skills are essential to success in this position.
You will be joining as the founding team of a biotech startup that has long-term stability due to significant funding, but yet is very much in the startup phase. Due to the early and exciting phase of growth, there are ample opportunities for significant impact. You will work closely with a very talented team, learn a broad range of skills, and help shape insitro’s culture, strategic direction, and outcomes. Join us and help make a difference to patients!
Nice to Have
Benefits at insitro
insitro is a data-driven drug discovery and development company using machine learning and high-throughput biology to transform the way that drugs are discovered and delivered to patients. The company is applying state-of-the-art technologies from bioengineering to create massive data sets that enable the power of modern machine learning methods to be brought to bear on key bottlenecks in pharmaceutical R&D. The resulting predictive models are used to accelerate target selection, to design and develop effective therapeutics, and to inform clinical strategy. insitro was launched in 2018 with a Series A of $100M funded by top investors including a16z, Arch Venture Partners, Foresite Capital, GV, and Third Rock Ventures. In 2019 the company announced a collaboration with Gilead Sciences in the area of NASH and, in mid 2020, announced a Series B financing of $143M including current investors and new investors Canada Pension Plan Investment Board (CPP Investments), T. Rowe Price, BlackRock, Casdin Capital and other leading investors. The company is located in South San Francisco, CA. For more information about insitro, please visit the company’s website at www. insitro.com.
Your application was submitted successfully.